JP6908785B2 - Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 - Google Patents
Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 Download PDFInfo
- Publication number
- JP6908785B2 JP6908785B2 JP2020524788A JP2020524788A JP6908785B2 JP 6908785 B2 JP6908785 B2 JP 6908785B2 JP 2020524788 A JP2020524788 A JP 2020524788A JP 2020524788 A JP2020524788 A JP 2020524788A JP 6908785 B2 JP6908785 B2 JP 6908785B2
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- protein
- gcc2
- exosome
- exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Description
したがって、非侵襲性、高感度、及び高特異性における癌の早期診断法の開発が求められている実状であるが、現在まで、癌の診断において早期に特異的に病巣を検知し、発病可否を判断する分子的な診断技術はほとんどなく、さらに、特定の癌に特異的に適用される方法は存在しない状況である。
5種の肺癌細胞株(H522、A549、H1650、PC9、H1299)をそれぞれ直径150mmのディッシュで培養した。ここで、超高速遠心分離機を用いて120、000gで4時間の間に遠心分離し、エクソソームを除去したFBS(Fetal Bovine Serum)の上層液を培養液として使用した。前記培養液を用いて、細胞が70−80%confluency状態になるよう2−3日間連続培養した。
前記実施形態1により選別したGCC2遺伝子の細胞内の発現水準を確認するため、定量的な逆転写重合酵素連鎖反応(qRT−PCR)を行った。
GCC2は、エクソソームの生成に関わっているものと推定されるタンパク質であるため、正常細胞株(HPAECs)と肺癌細胞株(H1299、H522)におけるエクソソームの分泌量を測定した。エクソソームの分泌量は、DLS(Dynamic Light Scattering)を用いて間接的に測定した。
前記実施形態1により収得したエクソソーム内のGCC2タンパク質の発現水準を確認するため、ウェスタンブロッティングを実施した。
GCC2タンパク質を含むエクソソームが肺癌診断又は予後予測用マーカーとして利用可能であるか否かを確認するため、下記のような試験を行った。
Claims (7)
- エクソソーム(exosome)内のGCC2(GRIP and coiled−coil domain−containing protein)タンパク質からなる、肺癌診断用マーカー組成物。
- エクソソーム(exosome)内のGCC2(GRIP and coiled−coil domain−containing protein)タンパク質に特異的に結合するプライマー又はプローブを含む、肺癌診断用組成物。
- エクソソーム(exosome)内のGCC2(GRIP and coiled−coil domain−containing protein)タンパク質に特異的に結合する抗体を含む、肺癌診断用組成物。
- 請求項2又は請求項3の組成物を含む、肺癌診断用キット。
- 前記キットは、RT−PCRキット、マイクロアレイチップキット、DNAキット、及びタンパク質チップキットからなる群から選択される1つ以上である、請求項4に記載の肺癌診断用キット。
- (a)生物学的試料からエクソソーム(exosome)を分離するステップと、
(b)前記エクソソーム内のGCC2(GRIP and coiled−coil domain−containing protein)タンパク質の発現水準を測定するステップとを含む、肺癌診断に必要な情報を提供する方法。 - 前記生物学的試料は、全血、血清、血漿、唾液、尿、喀痰、リンパ液、及び細胞からなる群から選択される1つ以上である、請求項6に記載の肺癌診断に必要な情報を提供する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170147510A KR102080887B1 (ko) | 2017-11-07 | 2017-11-07 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
KR10-2017-0147510 | 2017-11-07 | ||
PCT/KR2018/013220 WO2019093717A2 (ko) | 2017-11-07 | 2018-11-02 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021501897A JP2021501897A (ja) | 2021-01-21 |
JP6908785B2 true JP6908785B2 (ja) | 2021-07-28 |
Family
ID=66438917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524788A Active JP6908785B2 (ja) | 2017-11-07 | 2018-11-02 | Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20210018505A1 (ja) |
JP (1) | JP6908785B2 (ja) |
KR (1) | KR102080887B1 (ja) |
CN (1) | CN111373056A (ja) |
WO (1) | WO2019093717A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102350603B1 (ko) | 2019-04-03 | 2022-01-14 | 고려대학교 산학협력단 | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
KR102318328B1 (ko) * | 2020-04-13 | 2021-10-27 | 고려대학교 산학협력단 | Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
KR20230084704A (ko) | 2021-12-06 | 2023-06-13 | 주식회사 엑소퍼트 | Gcc2 억제제를 유효성분으로 포함하는 폐암 예방 또는 치료용 조성물 |
KR20240017323A (ko) | 2022-07-29 | 2024-02-07 | 고려대학교 산학협력단 | Gcc2 발현 억제제를 유효성분으로 포함하는 폐암 예방또는 치료용 약학적 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2154245B1 (en) * | 2005-09-02 | 2015-11-11 | Toray Industries, Inc. | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient |
US20110038801A1 (en) * | 2007-12-21 | 2011-02-17 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer |
US20120058492A1 (en) * | 2008-01-25 | 2012-03-08 | Hansabiomed Ou | Method and a Kit To Detect Malignant Tumors and Provide a Prognosis |
US7897356B2 (en) * | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
WO2010115077A2 (en) * | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Biomarker panels for barrett's esophagus and esophageal adenocarcinoma |
ES2700877T3 (es) * | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
JP5918694B2 (ja) * | 2009-05-12 | 2016-05-18 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 前立腺がんのマーカーとしてのホスホジエステラーゼ9a |
US9816998B2 (en) * | 2011-04-01 | 2017-11-14 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
SG11201406855TA (en) * | 2012-04-27 | 2014-11-27 | Millennium Pharm Inc | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
KR20160133740A (ko) * | 2015-05-13 | 2016-11-23 | 경북대학교 산학협력단 | 파이브로넥틴 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물 |
CN109563547A (zh) * | 2016-04-15 | 2019-04-02 | 外来体诊断公司 | 间变性淋巴瘤激酶(alk)核酸和alk融合转录物的基于血浆的检测及其在癌症诊断和治疗中的用途 |
-
2017
- 2017-11-07 KR KR1020170147510A patent/KR102080887B1/ko active IP Right Grant
-
2018
- 2018-11-02 US US16/762,140 patent/US20210018505A1/en not_active Abandoned
- 2018-11-02 WO PCT/KR2018/013220 patent/WO2019093717A2/ko active Application Filing
- 2018-11-02 CN CN201880072074.2A patent/CN111373056A/zh active Pending
- 2018-11-02 JP JP2020524788A patent/JP6908785B2/ja active Active
-
2021
- 2021-11-30 US US17/539,030 patent/US20220196664A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102080887B1 (ko) | 2020-02-24 |
KR20190051641A (ko) | 2019-05-15 |
US20210018505A1 (en) | 2021-01-21 |
US20220196664A1 (en) | 2022-06-23 |
JP2021501897A (ja) | 2021-01-21 |
WO2019093717A3 (ko) | 2019-06-27 |
WO2019093717A2 (ko) | 2019-05-16 |
CN111373056A (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6908785B2 (ja) | Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 | |
US20160209415A1 (en) | Method to predict or diagnose a colorectal cancer | |
Tokuishi et al. | Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma | |
Shin et al. | Identification of ganglioside GM 2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes | |
Wang et al. | Long non-coding RNA AK093407 promotes proliferation and inhibits apoptosis of human osteosarcoma cells via STAT3 activation | |
US20210116459A1 (en) | Biomarkers and uses thereof | |
US20150338412A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit for lung cancer | |
KR102328932B1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커 | |
KR101995189B1 (ko) | 비침습적 체외진단을 위한 간암 진단용 바이오마커 조성물 및 이를 포함하는 키트 | |
US20140248637A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
KR101334123B1 (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 | |
KR101358810B1 (ko) | 방사선 피폭 진단용 마커 igfbp-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 | |
JP7222117B2 (ja) | Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 | |
KR102350603B1 (ko) | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 | |
EP2772759B1 (en) | Composition for diagnosis of lung cancer | |
JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
KR102318328B1 (ko) | Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 | |
CN111289749A (zh) | C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用 | |
US20230045066A1 (en) | Biomarkers for diagnosing breast cancer and uses thereof | |
CN108982876B (zh) | Saa1检测剂在制备用于诊断过敏性紫癜肾炎的试剂盒中的应用 | |
Dunn | Unbiased global proteomic profiling of patient-derived meningiomas of all grades to identify molecular signatures of differentially expressed proteins and phosphoproteins. | |
Hassan | The Relationship Between Obesity and Breast Cancer on the Molecular Level | |
CN117778558A (zh) | Igfbp3基因在制备筛查宫腔粘连的相关产品的应用 | |
KR20240009366A (ko) | 초기 알츠하이머병 진단용 바이오마커 및 이의 용도 | |
KR20230020820A (ko) | 유방암 진단용 바이오마커 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210701 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6908785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |